MarketsandMarkets
Roche Diagnostics (Switzerland), Abbott Laboratories (U.S.), Agilent Technologies (U.S.), QIAGEN N.V. (Netherlands), and Thermo Fisher Scientific Inc. (U.S.)
(PRWEB) October 08, 2014
The "Companion Diagnostics Market by Technology (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry), Application (Breast, Lung cancer) & End-user (Pharmaceutical Companies, Reference Lab)- Global Trends & Forecasts to 2019". The global companion diagnostics market is expected to reach $8,730.7 million by 2019 from $3136.9 million in 2014, at a CAGR of 22.7% during the forecast period (2014 to 2019).
Browse 57 market data tables with 36 figures spread through 142 pages and in-depth TOC on "Companion Diagnostics Market"
http://www.marketsandmarkets.com/Market-Reports/companion-diagnostics-market-155571681.html
Early buyers will receive 10% customization on this report.
"Next-generation Sequencing (NGS)-based Companion Diagnostic Tests to Capture a Larger Market Share in Chronic and Life Threatening Diseases in the Future"
Advanced technologies such as next-generation sequencing (NGS), increasing adoption of companion diagnostics kits/tests by the pharmaceutical industry, and encouragement from regulatory bodies are expected to boost the global companion diagnostics market. This market is segmented by technology, application, and end user. Technologies are further subsegmented into immunohistochemistry, in situ hybridization (fluoroscent ISH and chromogenic ISH), polymerase chain reaction (PCR), and next-generation sequencing (NGS)-based tests.
Ask for PDF Brochure @ http://www.marketsandmarkets.com/pdfdownload.asp?id=155571681
Increasing costs of drug discovery; continuous focus on customized medicines for cancer; infectious, cardiovascular, neurological, and autoimmune diseases; and the need for technically advanced diagnostics has stimulated pharmaceutical firms to enter into the companion diagnostics market. In 2013, many new molecular entities (NMEs) were approved by a pharmacogenomic biomarker from the FDA. However, non-validated home brew tests employed by reference laboratories pose a major threat to validated companion diagnostic kits globally, as they are easily available and have faster approval procedures. In addition, different reimbursement policies followed by different regions may hinder the growth of the companion diagnostics market.
NGS-based companion diagnostics is one of the major factors that will drive the companion diagnostics market owing to its capability of identifying multiple genes at a single time. This in turn encouraged the adoption of diagnostic tests in the earlier clinical phase and ensured accurate treatments. Currently, NGS-based companion diagnostics tests are available for cystic fibrosis and the companion diagnostic manufacturers are engaged in developing tests for other chronic and life threatening diseases. To capture this market, pharmaceutical firms are striving to enter into the global companion diagnostics market through strategic acquisitions and collaborations with NGS platform diagnostic firms. Moreover, the end results of NGS is superior as compared to other technologies, as NGS provides a wider definition of genome sequencing that will fuel the adoption of NGS-based companion diagnostics in the future.
The growth in the companion diagnostics market is attributed to the growing need of personalized cancer treatment and tailored medications, increasing adoption of companion diagnostic tests by end users such as pharmaceutical and biotechnology firms and reference laboratories, and encouragement by regulatory bodies such as FDA and EMA to implement developments of companion diagnostic test at the early stages of drug development procedures. The oncology segment in the pharmaceutical industry and reference laboratories has been the major growth driver for the market.
Speak to Analyst for Further Inquiry @ http://www.marketsandmarkets.com/speaktoanalyst.asp?id=155571681
This study also illustrates the major market players who have made a remarkable contribution in the global companion diagnostics market. The major players of this market are Roche Diagnostics (Switzerland), Abbott Laboratories (U.S.), Agilent Technologies (U.S.), Thermo Fisher Scientific Inc. (U.S.), and QIAGEN N.V. (Netherlands).
Browse Related Reports:
Tissue Diagnostics Market by Technology (Immunohistochemistry, in Situ Hybridization, Digital pathology & Workflow, Special Staining), Disease (Breast Cancer, Gastric Cancer, Lymphoma, Prostate Cancer, Non Small Cell Lung Cancer and Others), Product (Instruments and Consumables), End-Users (Hospitals, Pharmaceutical companies, Research Laboratories, Contract Research Organizations and Others) & by Region (The Americas, Europe, BRIC, Japan & RoW) - Trends & Forecast to 2018
http://www.marketsandmarkets.com/Market-Reports/tissue-diagnostics-market-1063949.html
Molecular Diagnostics Market by Application (Infectious Disease, Oncology, Genetics, Microbiology), Technology (PCR, INAAT, DNA Sequencing), End User (Hospital, Laboratories), Product (Instruments, Reagent, Service, Software) - Global Forecasts to 2018
http://www.marketsandmarkets.com/Market-Reports/molecular-diagnostic-market-833.html
About MarketsandMarkets
MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.
MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals, including advanced materials, automotive and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, semiconductor and electronics, and telecommunications and IT.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
Contact:
Mr. Rohan
North - Dominion Plaza,
17304,Preston Road,
Suite 800, Dallas, TX 75252
Tel: +1-888-600-6441
Email: sales(at)marketsandmarkets(dot)com
Visit MarketsandMarkets Blog@ http://mnmblog.org/market-research/healthcare/biotechnology
Connect with us on LinkedIn@ http://www.linkedin.com/company/marketsandmarkets